Predictive value of mitotic figure counts in tumor progression of non-invasive high-grade papillary urothelial carcinoma of the urinary bladder: A retrospective study from a single cancer center

有丝分裂象计数对非侵袭性高级别膀胱乳头状尿路上皮癌肿瘤进展的预测价值:一项来自单一癌症中心的回顾性研究

阅读:1

Abstract

BACKGROUND: Urothelial carcinoma (UC) is the most common type of bladder malignancy. Although the majority of UC present as non-invasive tumors, a subset of them progress into invasive cancer and cause significant morbidity and mortality. OBJECTIVE: In this study, we examined the association between tumor mitotic activity associated and the progression of non-invasive high-grade papillary UC of the bladder. METHODS: Forty-four cases of tumors that met the selection criteria were retrieved from the Department of Pathology archives, and, for each case, mitotic figures were counted in 10 high-power fields (HPF) by two independent pathologists. Tumor progression was defined as the invasion of the tumor into the subepithelial connective tissue (lamina propria) or beyond during follow-ups. In addition, tumors that later exhibited distant metastases were included in the tumor progression group. RESULTS: Our study revealed that the average mitotic count per 10 HPF in the tumor progression group was significantly higher (p = 0.001) than in the progression-free group. Furthermore, tumors with more than three mitotic counts per HPF in initial biopsies posed a high risk of tumor progression within the 19.5 ± 6.1 months of follow-ups. CONCLUSION: The findings of our study provided valuable information for further stratification of risk factors among patients with non-invasive high-grade papillary UC of the bladder. Patients with high mitotic figure count in their initial biopsies should be monitored closely or treated earlier to prevent their tumors from progressing into invasive carcinoma.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。